Insider Selling: STERIS (NYSE:STE) CEO Sells 3,054 Shares of Stock

Posted by Stanley Muller on Jun 8th, 2026

STERIS plc (NYSE:STE – Get Free Report) CEO Daniel Carestio sold 3,054 shares of STERIS stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $214.64, for a total transaction of $655,510.56. Following the sale, the chief executive officer directly owned 65,021 shares of the company’s stock, valued at $13,956,107.44. This trade represents a 4.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

STERIS Stock Down 1.0%

Shares of NYSE:STE traded down $2.16 during trading on Monday, reaching $210.19. 658,842 shares of the company traded hands, compared to its average volume of 798,173. The firm has a fifty day simple moving average of $217.24 and a 200 day simple moving average of $238.96. The firm has a market cap of $20.51 billion, a P/E ratio of 26.51 and a beta of 0.93. STERIS plc has a 1-year low of $195.14 and a 1-year high of $269.44. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25.

STERIS (NYSE:STE – Get Free Report) last issued its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business earned $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts anticipate that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is 31.78%.

Wall Street Analyst Weigh In

STE has been the topic of several recent analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a report on Thursday, May 21st. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday. KeyCorp dropped their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Finally, Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.00.

Read Our Latest Report on STERIS

Institutional Trading of STERIS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Trust Co. of Vermont increased its stake in STERIS by 30.2% in the fourth quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 38 shares during the period. Bailard Inc. increased its stake in STERIS by 3.5% in the fourth quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock valued at $283,000 after acquiring an additional 38 shares during the period. Magnolia Capital Advisors LLC increased its stake in STERIS by 1.2% in the third quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock valued at $888,000 after acquiring an additional 41 shares during the period. Colonial Trust Co SC increased its stake in STERIS by 0.3% in the third quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock valued at $3,051,000 after acquiring an additional 42 shares during the period. Finally, Geneos Wealth Management Inc. increased its stake in STERIS by 34.9% in the second quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 45 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.